SELECT * FROM `stock_list` where symbol='01177' AND exchange = 'HKSE' limit 0,1
SELECT * FROM `stock_list` where symbol='01177' AND exchange = 'HKSE' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "01177" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Sino Biopharmaceutical (HKSE:01177) Cash Flow from Disconti
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Cash Flow from Discontinued Operations

Sino Biopharmaceutical (HKSE:01177) Cash Flow from Discontinued Operations : HK$0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Sino Biopharmaceutical's cash flow from discontinued operations for the six months ended in Dec. 2023 was HK$0 Mil. It means Sino Biopharmaceutical received HK$0 Mil from the sale of part of business quarterly. Sino Biopharmaceutical's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0 Mil.


Sino Biopharmaceutical Cash Flow from Discontinued Operations Historical Data

The historical data trend for Sino Biopharmaceutical's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Cash Flow from Discontinued Operations Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sino Biopharmaceutical Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (HKSE:01177) Business Description

Industry
Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines